HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited (HCG.NS) Stock Competitors & Peer Comparison
See (HCG.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCG.NS | ₹574.60 | -0.92% | 81B | 422.50 | ₹1.36 | N/A |
| APOLLOHOSP.BO | ₹7,778.55 | -0.05% | 1.1T | 62.21 | ₹125.04 | +0.26% |
| APOLLOHOSP.NS | ₹7,775.00 | -0.10% | 1.1T | 62.17 | ₹125.07 | +0.26% |
| MAXHEALTH.BO | ₹1,110.00 | +1.90% | 1.1T | 76.50 | ₹14.51 | +0.14% |
| MAXHEALTH.NS | ₹1,109.90 | +2.00% | 1.1T | 76.12 | ₹14.58 | +0.14% |
| FORTIS.BO | ₹964.05 | +3.57% | 727.8B | 75.97 | ₹12.69 | +0.11% |
| FORTIS.NS | ₹963.65 | +3.53% | 727.5B | 75.94 | ₹12.69 | +0.11% |
| NH.NS | ₹1,851.40 | -0.69% | 376B | 48.30 | ₹38.33 | +0.24% |
| NH.BO | ₹1,849.80 | -0.70% | 375.7B | 44.51 | ₹41.56 | +0.24% |
| ASTERDM.NS | ₹649.45 | +1.07% | 335.7B | 101.00 | ₹6.43 | +0.78% |
Stock Comparison
HCG.NS vs APOLLOHOSP.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, APOLLOHOSP.BO has a market cap of 1.1T. Regarding current trading prices, HCG.NS is priced at ₹574.60, while APOLLOHOSP.BO trades at ₹7,778.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas APOLLOHOSP.BO's P/E ratio is 62.21. In terms of profitability, HCG.NS's ROE is +0.02%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check APOLLOHOSP.BO's competition here
HCG.NS vs APOLLOHOSP.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, APOLLOHOSP.NS has a market cap of 1.1T. Regarding current trading prices, HCG.NS is priced at ₹574.60, while APOLLOHOSP.NS trades at ₹7,775.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas APOLLOHOSP.NS's P/E ratio is 62.17. In terms of profitability, HCG.NS's ROE is +0.02%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check APOLLOHOSP.NS's competition here
HCG.NS vs MAXHEALTH.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MAXHEALTH.BO has a market cap of 1.1T. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MAXHEALTH.BO trades at ₹1,110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MAXHEALTH.BO's P/E ratio is 76.50. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXHEALTH.BO's competition here
HCG.NS vs MAXHEALTH.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MAXHEALTH.NS has a market cap of 1.1T. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MAXHEALTH.NS trades at ₹1,109.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MAXHEALTH.NS's P/E ratio is 76.12. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXHEALTH.NS's competition here
HCG.NS vs FORTIS.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, FORTIS.BO has a market cap of 727.8B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while FORTIS.BO trades at ₹964.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas FORTIS.BO's P/E ratio is 75.97. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to FORTIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTIS.BO's competition here
HCG.NS vs FORTIS.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, FORTIS.NS has a market cap of 727.5B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while FORTIS.NS trades at ₹963.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas FORTIS.NS's P/E ratio is 75.94. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTIS.NS's competition here
HCG.NS vs NH.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, NH.NS has a market cap of 376B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while NH.NS trades at ₹1,851.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas NH.NS's P/E ratio is 48.30. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to NH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NH.NS's competition here
HCG.NS vs NH.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, NH.BO has a market cap of 375.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while NH.BO trades at ₹1,849.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas NH.BO's P/E ratio is 44.51. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NH.BO's competition here
HCG.NS vs ASTERDM.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ASTERDM.NS has a market cap of 335.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ASTERDM.NS trades at ₹649.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ASTERDM.NS's P/E ratio is 101.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASTERDM.NS's ROE of +0.09%. Regarding short-term risk, HCG.NS is more volatile compared to ASTERDM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ASTERDM.NS's competition here
HCG.NS vs ASTERDM.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ASTERDM.BO has a market cap of 335.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ASTERDM.BO trades at ₹649.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ASTERDM.BO's P/E ratio is 101.95. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASTERDM.BO's ROE of +0.09%. Regarding short-term risk, HCG.NS is more volatile compared to ASTERDM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ASTERDM.BO's competition here
HCG.NS vs MEDANTA.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MEDANTA.NS has a market cap of 312.3B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MEDANTA.NS trades at ₹1,161.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MEDANTA.NS's P/E ratio is 60.76. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MEDANTA.NS's competition here
HCG.NS vs MEDANTA.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MEDANTA.BO has a market cap of 312B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MEDANTA.BO trades at ₹1,161.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MEDANTA.BO's P/E ratio is 60.73. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MEDANTA.BO's competition here
HCG.NS vs KIMS.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KIMS.NS has a market cap of 297.4B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KIMS.NS trades at ₹743.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KIMS.NS's P/E ratio is 98.97. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KIMS.NS's ROE of +0.13%. Regarding short-term risk, HCG.NS is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KIMS.NS's competition here
HCG.NS vs KIMS.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KIMS.BO has a market cap of 297.3B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KIMS.BO trades at ₹742.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KIMS.BO's P/E ratio is 99.32. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KIMS.BO's ROE of +0.13%. Regarding short-term risk, HCG.NS is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KIMS.BO's competition here
HCG.NS vs RAINBOW.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, RAINBOW.BO has a market cap of 122.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while RAINBOW.BO trades at ₹1,207.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas RAINBOW.BO's P/E ratio is 47.80. In terms of profitability, HCG.NS's ROE is +0.02%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, HCG.NS is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check RAINBOW.BO's competition here
HCG.NS vs RAINBOW.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, RAINBOW.NS has a market cap of 122.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while RAINBOW.NS trades at ₹1,207.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas RAINBOW.NS's P/E ratio is 47.97. In terms of profitability, HCG.NS's ROE is +0.02%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, HCG.NS is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check RAINBOW.NS's competition here
HCG.NS vs JLHL.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, JLHL.NS has a market cap of 85.6B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while JLHL.NS trades at ₹1,305.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas JLHL.NS's P/E ratio is 45.37. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, HCG.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check JLHL.NS's competition here
HCG.NS vs JLHL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, JLHL.BO has a market cap of 85.5B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while JLHL.BO trades at ₹1,304.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas JLHL.BO's P/E ratio is 45.17. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, HCG.NS is less volatile compared to JLHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check JLHL.BO's competition here
HCG.NS vs HCG.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, HCG.BO has a market cap of 81B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while HCG.BO trades at ₹574.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas HCG.BO's P/E ratio is 422.39. In terms of profitability, HCG.NS's ROE is +0.02%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, HCG.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check HCG.BO's competition here
HCG.NS vs YATHARTH.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, YATHARTH.NS has a market cap of 67.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while YATHARTH.NS trades at ₹697.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas YATHARTH.NS's P/E ratio is 40.12. In terms of profitability, HCG.NS's ROE is +0.02%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to YATHARTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check YATHARTH.NS's competition here
HCG.NS vs YATHARTH.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, YATHARTH.BO has a market cap of 67.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while YATHARTH.BO trades at ₹697.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas YATHARTH.BO's P/E ratio is 40.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to YATHARTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check YATHARTH.BO's competition here
HCG.NS vs KOVAI.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KOVAI.BO has a market cap of 56.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KOVAI.BO trades at ₹5,132.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KOVAI.BO's P/E ratio is 23.85. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, HCG.NS is more volatile compared to KOVAI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check KOVAI.BO's competition here
HCG.NS vs ARTEMISMED.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ARTEMISMED.BO has a market cap of 37.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ARTEMISMED.BO trades at ₹235.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ARTEMISMED.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to ARTEMISMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ARTEMISMED.BO's competition here
HCG.NS vs ARTEMISMED.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ARTEMISMED.NS has a market cap of 37B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ARTEMISMED.NS trades at ₹234.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ARTEMISMED.NS's P/E ratio is 102.55. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ARTEMISMED.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to ARTEMISMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ARTEMISMED.NS's competition here
HCG.NS vs INDRAMEDCO.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, INDRAMEDCO.BO has a market cap of 37B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while INDRAMEDCO.BO trades at ₹403.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas INDRAMEDCO.BO's P/E ratio is 20.23. In terms of profitability, HCG.NS's ROE is +0.02%, compared to INDRAMEDCO.BO's ROE of +0.31%. Regarding short-term risk, HCG.NS is more volatile compared to INDRAMEDCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check INDRAMEDCO.BO's competition here
HCG.NS vs INDRAMEDCO.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, INDRAMEDCO.NS has a market cap of 36.8B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while INDRAMEDCO.NS trades at ₹401.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas INDRAMEDCO.NS's P/E ratio is 20.14. In terms of profitability, HCG.NS's ROE is +0.02%, compared to INDRAMEDCO.NS's ROE of +0.31%. Regarding short-term risk, HCG.NS is more volatile compared to INDRAMEDCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check INDRAMEDCO.NS's competition here
HCG.NS vs KOVAI.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KOVAI.NS has a market cap of 35.3B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KOVAI.NS trades at ₹2,581.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KOVAI.NS's P/E ratio is 20.74. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, HCG.NS is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KOVAI.NS's competition here
HCG.NS vs DRAGARWQ.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, DRAGARWQ.BO has a market cap of 21.8B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while DRAGARWQ.BO trades at ₹4,641.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas DRAGARWQ.BO's P/E ratio is 31.51. In terms of profitability, HCG.NS's ROE is +0.02%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, HCG.NS is more volatile compared to DRAGARWQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check DRAGARWQ.BO's competition here
HCG.NS vs SHALBY.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, SHALBY.NS has a market cap of 16.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while SHALBY.NS trades at ₹155.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas SHALBY.NS's P/E ratio is 199.28. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to SHALBY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check SHALBY.NS's competition here
HCG.NS vs SHALBY.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, SHALBY.BO has a market cap of 16.7B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while SHALBY.BO trades at ₹155.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas SHALBY.BO's P/E ratio is 199.17. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to SHALBY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check SHALBY.BO's competition here
HCG.NS vs KMCSHIL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KMCSHIL.BO has a market cap of 14B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KMCSHIL.BO trades at ₹86.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KMCSHIL.BO's P/E ratio is 38.41. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KMCSHIL.BO's ROE of +0.22%. Regarding short-term risk, HCG.NS is less volatile compared to KMCSHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KMCSHIL.BO's competition here
HCG.NS vs MAXINDIA.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MAXINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXINDIA.BO's competition here
HCG.NS vs MAXIND.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MAXIND.NS has a market cap of 8.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MAXIND.NS trades at ₹155.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MAXIND.NS's P/E ratio is -5.23. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, HCG.NS is more volatile compared to MAXIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXIND.NS's competition here
HCG.NS vs ASARFI.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ASARFI.BO has a market cap of 3.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ASARFI.BO trades at ₹161.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ASARFI.BO's P/E ratio is 19.46. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASARFI.BO's ROE of +0.14%. Regarding short-term risk, HCG.NS is more volatile compared to ASARFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ASARFI.BO's competition here
HCG.NS vs LOTUSEYE.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, LOTUSEYE.BO has a market cap of 2.3B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while LOTUSEYE.BO trades at ₹109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas LOTUSEYE.BO's P/E ratio is 351.61. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to LOTUSEYE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check LOTUSEYE.BO's competition here
HCG.NS vs LOTUSEYE.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, LOTUSEYE.NS has a market cap of 2.2B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while LOTUSEYE.NS trades at ₹107.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas LOTUSEYE.NS's P/E ratio is 337.47. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to LOTUSEYE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check LOTUSEYE.NS's competition here
HCG.NS vs AASHKA.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, AASHKA.BO has a market cap of 1.9B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while AASHKA.BO trades at ₹80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas AASHKA.BO's P/E ratio is 76.92. In terms of profitability, HCG.NS's ROE is +0.02%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, HCG.NS is more volatile compared to AASHKA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check AASHKA.BO's competition here
HCG.NS vs LEHIL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check LEHIL.BO's competition here
HCG.NS vs JSTL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, JSTL.BO has a market cap of 1.1B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while JSTL.BO trades at ₹68.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas JSTL.BO's P/E ratio is -53.54. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, HCG.NS is more volatile compared to JSTL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check JSTL.BO's competition here
HCG.NS vs FORTISMLR.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, FORTISMLR.BO has a market cap of 1B. Regarding current trading prices, HCG.NS is priced at ₹574.60, while FORTISMLR.BO trades at ₹53.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas FORTISMLR.BO's P/E ratio is 22.24. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to FORTISMLR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTISMLR.BO's competition here
HCG.NS vs ASPIRA.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ASPIRA.BO has a market cap of 587.5M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ASPIRA.BO trades at ₹57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ASPIRA.BO's P/E ratio is 41.36. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check ASPIRA.BO's competition here
HCG.NS vs NGIND.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, NGIND.BO has a market cap of 469.1M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while NGIND.BO trades at ₹140.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas NGIND.BO's P/E ratio is 9.58. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, HCG.NS is more volatile compared to NGIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NGIND.BO's competition here
HCG.NS vs MEDINOV.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, HCG.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check MEDINOV.BO's competition here
HCG.NS vs CMMHOSP.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, CMMHOSP.BO has a market cap of 303.6M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while CMMHOSP.BO trades at ₹40.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas CMMHOSP.BO's P/E ratio is -33.32. In terms of profitability, HCG.NS's ROE is +0.02%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, HCG.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check CMMHOSP.BO's competition here
HCG.NS vs TEJNAKSH.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, TEJNAKSH.BO has a market cap of 282.6M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while TEJNAKSH.BO trades at ₹13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas TEJNAKSH.BO's P/E ratio is 20.46. In terms of profitability, HCG.NS's ROE is +0.02%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, HCG.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check TEJNAKSH.BO's competition here
HCG.NS vs KKSHL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, KKSHL.BO has a market cap of 245.1M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while KKSHL.BO trades at ₹36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas KKSHL.BO's P/E ratio is -23.84. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, HCG.NS is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check KKSHL.BO's competition here
HCG.NS vs SML.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, SML.BO has a market cap of 229.3M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while SML.BO trades at ₹53.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas SML.BO's P/E ratio is -22.98. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SML.BO's ROE of -1.02%. Regarding short-term risk, HCG.NS is more volatile compared to SML.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check SML.BO's competition here
HCG.NS vs FAMILYCARE.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, FAMILYCARE.BO has a market cap of 180.9M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while FAMILYCARE.BO trades at ₹3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas FAMILYCARE.BO's P/E ratio is -3.45. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, HCG.NS is more volatile compared to FAMILYCARE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FAMILYCARE.BO's competition here
HCG.NS vs GLHRL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, GLHRL.BO has a market cap of 173.3M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while GLHRL.BO trades at ₹16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas GLHRL.BO's P/E ratio is -7.33. In terms of profitability, HCG.NS's ROE is +0.02%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check GLHRL.BO's competition here
HCG.NS vs LOOKS.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, LOOKS.BO has a market cap of 106.2M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while LOOKS.BO trades at ₹10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas LOOKS.BO's P/E ratio is 50.55. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to LOOKS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check LOOKS.BO's competition here
HCG.NS vs ZDHJERK.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, ZDHJERK.BO has a market cap of 100.4M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while ZDHJERK.BO trades at ₹24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas ZDHJERK.BO's P/E ratio is 38.28. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ZDHJERK.BO's competition here
HCG.NS vs GIANLIFE.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, GIANLIFE.BO has a market cap of 93M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while GIANLIFE.BO trades at ₹8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas GIANLIFE.BO's P/E ratio is -9.56. In terms of profitability, HCG.NS's ROE is +0.02%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, HCG.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check GIANLIFE.BO's competition here
HCG.NS vs DLCL.BO Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, DLCL.BO has a market cap of 68.8M. Regarding current trading prices, HCG.NS is priced at ₹574.60, while DLCL.BO trades at ₹15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas DLCL.BO's P/E ratio is 20.62. In terms of profitability, HCG.NS's ROE is +0.02%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, HCG.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check DLCL.BO's competition here
HCG.NS vs NEPHROCARE-ST.NS Comparison February 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 81B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, HCG.NS is priced at ₹574.60, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 422.50, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, HCG.NS is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NEPHROCARE-ST.NS's competition here